GTTX — GeneTether Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$1.94m
- CA$0.22m
- 50
- 38
- 73
- 53
Annual cashflow statement for GeneTether Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.087 | -0.073 | -1.64 | -1.72 | -0.688 |
| Non-Cash Items | — | 0 | 0.685 | 0.812 | 0.171 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.009 | 0.004 | 0.212 | -0.274 | 0.052 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Cash from Operating Activities | -0.095 | -0.069 | -0.74 | -1.18 | -0.465 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.08 | 0.104 | 0.875 | 3 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.015 | 0.035 | 0.134 | 1.62 | -0.432 |